文献速递急性肾损伤血液净化与透析

选择性细胞分离装置在危重患儿中的安全性与可行性

Use of the Selective Cytopheretic Device in Critically Ill Children.
PubMed 文献 · Kidney Int Rep · 2020-12-19

本研究由FDA资助,在4个儿科ICU纳入16例需CKRT的AKI合并多器官功能障碍患儿,评估SCD联合RCA维持回路iCa2+<0.40 mmol/l的安全性。结果显示SCD治疗可行且安全,无相关不良事件,75%存活至ICU出院,存活者60天均脱离透析。

要点

  • SCD联合RCA在危重患儿中可行,回路iCa2+<0.40 mmol/l维持时间占90.2%。
  • 未报告SCD相关不良事件,但样本量小无法作疗效声明。

核心结论

  • SCD治疗在需CKRT的危重患儿中可行且安全,观察到的75%存活率和100%肾脏恢复率提示可能有利的风险获益比。

研究设计与样本

  • FDA资助的前瞻性研究,4个儿科ICU纳入16例AKI合并多器官功能障碍接受CKRT的患儿,SCD整合于CKRT膜后,RCA维持回路iCa2+<0.40 mmol/l,治疗7天或至CKRT终止。

主要发现

  • 16例患儿平均年龄12.3±5.1岁,体重53.8±28.9 kg,中位PRISM II评分7(范围2-19)。
  • 回路iCa2+<0.40 mmol/l维持时间占SCD治疗的90.2%,中位SCD持续时间6天。
  • 未报告SCD相关不良事件。

临床怎么用

  • 在危重患儿CKRT中可考虑集成SCD并联合RCA维持回路iCa2+<0.40 mmol/l,但需注意证据来自小样本可行性研究。

局限性

  • 样本量小(16例),无法作出疗效声明,观察到的存活率和肾脏恢复率需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Critically ill children with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT) are at increased risk of death. The selective cytopheretic device (SCD) promotes an immunomodulatory effect when circuit ionized calcium (iCa2+) is maintained at <0.40 mmol/l with regional citrate anticoagulation (RCA). In a randomized trial of adult patients on CRRT, those treated with the SCD maintaining an iCa2+ <0.40 mmol/l had improved survival/dialysis independence. We conducted a US Food and Drug Administration (FDA)-sponsored study to evaluate safety and feasibility of the SCD in 16 critically ill children. METHODS: Four pediatric intensive care units (ICUs) enrolled children with AKI and multiorgan dysfunction receiving CKRT to receive the SCD integrated post-CKRT membrane. RCA was used to achieve a circuit iCa2+ level <0.40 mmol/l. Subjects received SCD treatment for 7 days or CKRT discontinuation, whichever came first. RESULTS: The FDA target enrollment of 16 subjects completed the study from December 2016 to February 2020. Mean age was 12.3 ± 5.1 years, weight was 53.8 ± 28.9 kg, and median Pediatric Risk of Mortality II was 7 (range 2-19). Circuit iCa2+ levels were maintained at <0.40 mmol/l for 90.2% of the SCD therapy time. Median SCD duration was 6 days. Fifteen subjects survived SCD therapy; 12 survived to ICU discharge. All ICU survivors were dialysis independent at 60 days. No SCD-related adverse events (AEs) were reported. CONCLUSION: Our data demonstrate that SCD therapy is feasible and safe in children who require CKRT. Although we cannot make efficacy claims, the 75% survival rate and 100% renal recovery rate observed suggest a possible favorable benefit-to-risk ratio.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Goldstein SL, Askenazi DJ, Basu RK, et al. Use of the Selective Cytopheretic Device in Critically Ill Children. Kidney Int Rep. 2020. PMID: 33732992. doi:10.1016/j.ekir.2020.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。